Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
MetadataShow full item record
AbstractThe ability of GH, via its mediator peptide IGF-1, to influence regulation of cellular growth has been the focus of much interest in recent years. In this review, we will explore the association between GH and cancer. Available experimental data support the suggestion that GH/IGF-1 status may influence neoplastic tissue growth. Extensive epidemiological data exist that also support a link between GH/IGF-1 status and cancer risk. Epidemiological studies of patients with acromegaly indicate an increased risk of colorectal cancer, although risk of other cancers is unproven, and a long-term follow-up study of children deficient in GH treated with pituitary-derived GH has indicated an increased risk of colorectal cancer. Conversely, extensive studies of the outcome of GH replacement in childhood cancer survivors show no evidence of an excess of de novo cancers, and more recent surveillance of children and adults treated with GH has revealed no increase in observed cancer risk. However, given the experimental evidence that indicates GH/IGF-1 provides an anti-apoptotic environment that may favour survival of genetically damaged cells, longer-term surveillance is necessary; over many years, even a subtle alteration in the environmental milieu in this direction, although not inducing cancer, could result in acceleration of carcinogenesis. Finally, even if GH/IGF-1 therapy does result in a small increase in cancer risk compared to untreated patients with GH deficiency, it is likely that the eventual risk will be the same as the general population. Such a restoration to normality will need to be balanced against the known morbidity of untreated GH deficiency.
CitationClin. Endocrinol. 2006, 64 (2):115-121
DescriptionKEYWORDS - CLASSIFICATION: adverse effects;Acromegaly;Adult;Animals;cancer epidemiology;complications;Child;Child Development;Colorectal Neoplasms;deficiency;epidemiology;etiology;Evaluation;Growth Hormone;Human Growth Hormone;Humans;Insulin-Like Growth Factor I;mechanisms of carcinogenesis;Neoplasm Recurrence,Local;Neoplasms;Neoplasms,Multiple Primary;physiology;physiopathology;Risk Factors;secretion;therapy.
- Does the GH-IGF axis play a role in cancer pathogenesis?
- Authors: Cohen P, Clemmons DR, Rosenfeld RG
- Issue date: 2000 Dec
- Acromegaly, growth hormone and cancer risk.
- Authors: Renehan AG, Brennan BM
- Issue date: 2008 Aug
- Role of growth hormone in chronic heart failure: therapeutic implications.
- Authors: Volterrani M, Giustina A, Manelli F, Cicoira MA, Lorusso R, Giordano A
- Issue date: 2000 Nov
- The GH-IGF-I axis and the cardiovascular system: clinical implications.
- Authors: Colao A
- Issue date: 2008 Sep
- Controversies in the risk of neoplasia in GH deficiency.
- Authors: Pekic S, Stojanovic M, Popovic V
- Issue date: 2017 Feb